Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - CMC Biologics
 More »

  • RuiYi Licenses mAb Development to China's Genor
    development of a cell line for RYI-008 by using the CHEF1® high-productivity expression plasmid of CMC Biologics, in a separate collaboration whose value was also not disclosed. ...
    5-16-2013
  • RuiYi, CMC Collaborate to Speed mAb Development
    CMC Biologics will use its CHEF1® high-productivity expression plasmid to accelerate development of a cell line for RuiYi's monoclonal antibody RYI-008, under a collaboration ...
    5-14-2013
  • People in the News
    Labrys Biologics added Marcelo Bigal, M.D., Ph.D. , as CMO; Michael Chang, Ph.D. , as vp ... and Henry Stern as executive director of CMC...Teva Pharmaceutical hired Ivana ...
    4-15-2013
  • Meeting the Bioassay Challenge
    At the center of CMC Biologics sits the analytical and formulation group, which develops bioassays and formulations that facilitate both upstream and downstream processes. A ...
    3-15-2013
  • People in the News
    Patrick Gallagher joined Kinex Pharmaceuticals as vp of business development and investor relations...CMC Biologics hired Mark W. Sawicki as vp of global business development. ...
    10-15-2012
  • CMOs Focus on Technology Improvements
    While new planned expansions have slowed, the CMO industry continues to take advantage of current biotech industry conditions. On July 31, CMC Biologics acquired Xoma's large-scale ...
    10-1-2012
  • People in the News
    Previously, Mayer was svp of business development at Biovail Pharmaceuticals. Prior to that, she held senior positions at Sanofi Aventis and Johnson & Johnson. CMC Biologics hired ...
    10-1-2012
  • Xoma Ends Busy Week with Third Deal
    The Boehringer Ingelheim agreement capped off a hectic week for Xoma. On Tuesday, CMC Biologics acquired Xoma's large-scale biomanufacturing plant in Berkeley, CA. This came one ...
    8-3-2012
  • Monoclonal Antibodies Enter Golden Age
    aid in establishing standardized unit operations and support CMC regulatory submissions. ... says Richard Hetrick, director of business development at Cytovance Biologics. ...
    8-1-2012
  • Double Deals for Xoma
    CMC Biologics acquired Xoma's large-scale biomanufacturing plant in Berkeley, CA. The 31,000 square foot facility houses three 2,750 L stainless steel bioreactors and two ...
    7-31-2012
  • Global Bioclusters Vie for Dominance in Battle Royale
    ... In March, BayBio, signed a memorandum of understanding with China Medical City (CMC) in ... In recent years, Bristol-Myers Squibb (BMS) completed a $750 million bulk biologics ...
    6-1-2012
  • Tech Tips: Single-Use Technology
    and CEO of Pristine Bioproduction; Morten Munk , vp, business development of CMC Biologics; Serge Runser, Ph.D. , head of global biopharmaceutical operations at Novartis ...
    3-1-2012
  • CMOs Investing in Capacity & Capabilities
    and faster turn-around for the smaller batch sizes often required by their clients. CMC Biologics is adding capacity at both its Bothell, WA, site and its Copenhagen facilities. ...
    7-1-2011
  • Demand for High-Tech Outsourcing Growing
    ... innovative pharmaceutical products," Morten Munk, vp of business development at CMC Biologics, said. "This is a long-term trend that is creating opportunities, particularly for ...
    3-1-2011
  • ProtAffin Wins €2.7M Grant for Preclinical Stage Glycan-Binding...
    The firm's preclinical pipeline is headed by PA401. In July ProtAffin signed a manufacturing contract for the candidate with CMC Biologics' Danish operations. The contract covers ...
    11-15-2010

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll